Finance

Lists
Why is CRL down 2,77%?
Dive Deeper
CRL:NYSE
Charles River Laboratories Intrtnl, Inc.
286,83 $
-2,77%
(-8,18) 1D
286,83 $
0,00% (0,00)
After hours
Closed: 1 қаз., 16:00:06 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRL...
Open
291,86 $
High
297,00 $
Low
284,61 $
Mkt. cap
13,69 млрд
Avg. vol.
946,04 м.
Volume
823,07 м.
52-wk high
303,30 $
52-wk low
146,20 $
EPS
-4,85 $
Beta
1,40
Shares outstanding
47,74 млн
No. of employees
19 мың
Open
291,86 $
High
297,00 $
Low
284,61 $
Mkt. cap
13,69 млрд
Avg. vol.
946,04 м.
Volume
823,07 м.
52-wk high
303,30 $
52-wk low
146,20 $
EPS
-4,85 $
Beta
1,40
Shares outstanding
47,74 млн
No. of employees
19 мың
News stories
From web sources and news partners
Profile
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients. Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Laboratories Intrtnl, Inc.
CEO-
Employees19 мың
Founded1947
HeadquartersWilmington, Массачусетс, Америка Құрама Штаттары
Sector-
Websitecriver.com
Analyst ratings
Based on 17 analysts giving stock ratings to CRL in the past 3 months
Strong buy
Buy
15
Hold
2
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for CRL in the last 3 months.
Highest
Current 286,83 $
357,00 $ (+24,46%)
Average
313,13 $ (+9,17%)
Lowest
219,00 $ (-23,65%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kevin Caliendo
UBS
Buy
Initiated
357,00 $
+24,5%
09/30/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
-
-
09/28/2026
David Windley
Jefferies
Buy
Maintained
340,00 $
+18,5%
09/28/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
320,00 $
+11,6%
09/25/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
330,00 $
+15,1%
09/25/2026
Ann Hynes
Mizuho Securities
Hold
Maintained
295,00 $
+2,8%
09/25/2026
Ryan Halsted
RBC Capital
Buy
Maintained
322,00 $
+12,3%
09/25/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
334,00 $
+16,4%
09/25/2026
Luke Sergott
Barclays
Buy
Maintained
330,00 $
+15,1%
09/24/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
325,00 $
+13,3%
09/25/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
09/24/2026
Unknown Analyst
Stephens
Buy
Initiated
320,00 $
+11,6%
09/22/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
300,00 $
+4,6%
09/21/2026
David Toung
Argus Research
Buy
Reiterated
330,00 $
+15,1%
09/16/2026
Casey Woodring
J.P. Morgan
Buy
Upgraded
310,00 $
+8,1%
08/05/2026
Michael Luo CFA
CLSA
Hold
Downgraded
219,00 $
-23,6%
07/20/2026
Patrick B Donnelly
Citi
Buy
Maintained
265,00 $
-7,6%
07/08/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
Charles Weston
RBC Capital
Buy
Initiated
215,00 $
-25%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
175,00 $
-39%
02/25/2026
Last report
2026 ж. 05 там.
Fiscal period
Q2 2026
EPS / Est. (USD)
3,02 $ / 2,73 $
+10,65%beat
Revenue / Est. (USD)
1,00 млрд / 977,20 млн
+2,75%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
1,00 млрд
994,23 млн
995,83 млн
1,00 млрд
Cost of goods sold
652,72 млн
665,36 млн
672,79 млн
625,06 млн
Cost of revenue
652,72 млн
665,36 млн
672,79 млн
625,06 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
173,64 млн
192,02 млн
149,12 млн
214,18 млн
Operating expense
201,05 млн
284,04 млн
164,46 млн
227,27 млн
Total operating expenses
853,77 млн
949,40 млн
837,25 млн
852,33 млн
Operating income
151,08 млн
44,83 млн
158,58 млн
151,74 млн
Other non operating income
-22,62 млн
27,72 млн
-123,11 млн
25,99 млн
EBT including unusual items
87,20 млн
-294,10 млн
-29,94 млн
53,17 млн
EBT excluding unusual items
104,48 млн
35,18 млн
8,62 млн
148,43 млн
Income tax expense
31,64 млн
-17,81 млн
-15,14 млн
53,93 млн
Effective tax rate
36,29%
6,06%
50,56%
101,43%
Other operating expenses
-
-
-
-
Net income
54,42 млн
-276,56 млн
-14,84 млн
-1,48 млн
Net profit margin
5,42%
-27,82%
-1,49%
-0,15%
Earnings per share
2,43
2,39
2,06
3,02
Interest and investment income
1,42 млн
1,02 млн
1,03 млн
1,03 млн
Interest expense
-25,40 млн
-23,78 млн
-26,74 млн
-30,34 млн
Net interest expenses
-23,98 млн
-22,76 млн
-25,71 млн
-29,31 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
236,25 млн
169,61 млн
225,73 млн
217,54 млн
Gain or loss from assets sale
-
-
117,98 млн
24,92 млн
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары